To Assess The Efficacy Of Methylene Blue Dye As A Single Technique In Breast Cancer Sentinel Lymph Node Biopsy
Aim: The aim of the present study was to assess the efficacy of methylene blue dye as a single technique in breast cancer sentinel lymph node biopsy.
Methods: The Prospective, Randomized, comparative study was conducted at Dr. D. Y. Patil Medical College, Hospital & Research Centre, Pimpri, Pune from September 2020 to September 2022. After obtaining approval from Institutional research Ethical board and written informed patient consent was taken. The Cases included all women with a FNA / Biopsy proven carcinoma breast.
Results: The mean age group of presentation was 52.04 ± 12.27 years. The youngest patient was 31 years at diagnosis, while the oldest patient was 74 years old. Highest frequency was seen in the 41-50 years category with 17 patients (34%), followed by 51-60 and 61-70 years, with 10 patients each. In the present study, 56% involved right side and 22% involved left side. In 57% cases, Right Upper Outer Quadrant was involved and in left side, 59.5% involved Left Upper Outer Quadrant. According to T stage, 60% were having T2 stage and 56% had grade 2 staging.
Conclusion: In conclusion, the breast cancer SNB has a favorable identification rate and predictive value, which were 90% and 93.3%, respectively, when 1% MBD injection is used as a single approach. This study shows that methylene blue dye by itself can localize sentinel nodes. According to our findings, the detection rate for the sentinel node(s) utilizing subareolar methylene blue is 90%, which is a high rate.